Associating antimicrobial susceptibility testing with clinical outcomes in cystic fibrosis: More rigor and less frequency?

Antimicrobial susceptibility testing (AST) is a mainstay in the management of cystic fibrosis (CF) bacterial lung infections (both acute and chronic), although more recently its clinical utility in CF has come into question [1]. In this issue of JCF, Somayaji et al., on behalf of the Antimicrobial Resistance in CF Working Group, performed a thoughtful and thorough systematic review of published studies on AST in CF and its association with clinical response [2]. This systematic review, which included a mixture of retrospective and prospective observational studies as well as randomized controlled trials, utilized the PICO (patient, intervention, comparator, outcome) format to create two specific research questions.

Source: Journal of Cystic Fibrosis - February 26, 2019 Category: Respiratory Medicine Authors: Rhonda D. Szczesniak, Jonathan D. Cogen, Margaret Rosenfeld Tags: Editorial Source Type: research